Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Benzer Materyaller

• Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
  Yazar:: Choy, Ernest, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis
  Yazar:: Choy, Ernest, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Treatment of Rheumatoid Arthritis With Anti–Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
  Yazar:: Choy, Ernest H., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
  Yazar:: Negoescu, Andra F., ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Dose Modification of Subcutaneous Tocilizumab in Patients with Rheumatoid Arthritis
  Yazar:: Best, Jennie H., ve diğerleri
  Baskı/Yayın Bilgisi: (2020)